RU2420328C2 - Method of treating breast cancer - Google Patents

Abstract

FIELD: medicine.

SUBSTANCE: invention refers to medicine, oncology, and can be used in complex treatment of malignant breast tumours. Patient's blood is sampled from a peripheral vein in two containers, 100 ml in each; inductors of an apparatus for physical therapy are placed oppositely on each side of a connector tube of a dropper to expose simultaneously to red light of wave length 670 nm, dose 1-5 J/cm² and field density 5 mT, frequency 0.3 Hz for 3 minutes. Doxorubicin 50 mg is added to the first container, while Methotrexate 25 mg, cyclopohsphane 600 mg, 5-fluorouracil 750 mg are added to the second container; the contents of the containers is incubated for 40 minutes at temperature 37°C and introduced in the patient on the 1st and 8th days of treatment. On the 3rd, 5th, 10th, 12th and 15th days of treatment, 5-fluorouracil 500 mg mixed with autoblood and incubated as described above is introduced. In 14 days after the last introduction of mixed autoblood and chemopreparation, the therapeutic modalities are repeated in the same order, doses and processing.

EFFECT: lower toxicity of the chemopreparations and tumour extension.

2 dwg, 1 ex

Description

The invention relates to medicine, more specifically to oncology, and can be used in the treatment of malignant breast tumors as one of the components of a comprehensive treatment.

A known method of treating breast cancer, comprising, as one of the components of the therapeutic effects, the introduction of antitumor chemotherapy drugs connected with autologous blood previously taken from a patient from a peripheral vein. Autologous blood is combined with various antitumor drugs and the mixture is injected intravenously on the 1st and 8th days of treatment. Single doses are used at the rate of 5-fluorouracil 1000-1500 mg / m ² , doxorubicin 100-150 mg / m ² , cyclophosphamide 1500-2000 mg / m ² (“Immediate results of the treatment of locally advanced breast cancer using autohemochemotherapy.” Salads R .N. Et al. “High Technologies in Oncology”, materials of the V All-Russian Congress of Oncologists, Kazan, 2000)

The introduction of antitumor chemotherapy drugs on autologous blood reduces the number of toxic side effects, but does not completely exclude them. As the authors themselves point out, 100% of patients had reversible allopecia, I-III degree leukopenia, in many cases there was nausea and vomiting at the beginning of treatment.

A known method of treating skin neoplasms when the affected area of the skin is exposed to the visible part of sunlight with a color range from 400 to 760 nm, focused and concentrated in the form of a spot for 2-20 minutes (patent No. 2143237, Bull. No. 36 from 12.27.99 ) The author has achieved high efficiency using the developed method for applying the color spectrum.

However, the use of the above method cannot be applied to the treatment of breast tumors. Performing it requires a special device for focusing sunlight and using only a certain color range. In addition, the duration of exposure also plays a significant role, as the necessary amount of autoblood is taken in 1.5-2 minutes. Taking into account the fact that the breast tumor is not located on the skin, but at various depths under it, the effectiveness of using the aforementioned method raises many doubts. The need to apply therapeutic effects in more effective ways and in the very near future after clarifying the diagnosis of education forces us to look for the most acceptable.

The aim of the invention is to reduce the size of the tumor and the ability to quickly remove it.

This goal is achieved by the fact that in the treatment room the patient is sampled from the peripheral vein in two containers of 100 ml each. The inductors of the physiotherapeutic apparatus are installed against each other on both sides of the connecting tube of the dropper, covering the tube from daylight, affecting the blood passing through the tube with red light at a wavelength of 670 nm, a dose of 1-5 J / cm ² and a magnetic field of 5 mT induction, 0.3 Hz for 3 minutes. In the first container, 50 mg of doxorubicin is added, in the second 25 mg of methotrexate, 750 mg of 5-fluorouracil and 600 mg of cyclophosphamide, the contents of the containers are incubated for 40 minutes at a temperature of 37 ° C, after which the patient is introduced on the 1st and 8th days treatment on the 3rd, 5th, 10th, 12th and 15th days of treatment, 500 mg of 5-fluorouracil connected with autologous blood and incubated as described is administered. 14 days after the 1st course of treatment, a second course of treatment is carried out, in which the exposure is repeated in the same order, similar doses and treatment.

A comparative analysis of the known methods of treating breast cancer and the developed one allows us to state the presence of novelty and differences.

The novelty of the proposed method lies in the simultaneous exposure to autologous blood of red light and a magnetic field. Subjected to this effect, autoblood incubated with chemotherapy has a pronounced effect on tumor cells, contributing to their regression and reducing the size of the tumor itself. In open sources of information from Russia, the CIS and foreign countries did not manage to find a similar method.

The inventive method is industrially feasible, it can be reproduced and repeatedly repeated in specialized medical institutions, cancer dispensaries and surgical hospitals of the general medical network.

The method is as follows: in the treatment room, the patient is sampled from the peripheral vein in two containers of 100 ml each. On both sides of the connecting tube of the dropper, inductors of the Gradient-3 apparatus are installed against each other, covering the connecting tube from daylight. Blood passing through the tube is simultaneously exposed to red light at a wavelength of 670 nm, a dose of 1-5 J / cm ² and a magnetic field of 5 mT induction, with a frequency of 0.3 Hz for 3 minutes. In the first container add 50 mg of doxorubicin, in the second 25 mg of methotrexate, 750 mg of 5-fluorouracil and 600 mg of cyclophosphamide; the contents of the containers are incubated for 40 minutes at a temperature of 37 ° C, after which the patient is administered on the 1st, 8th days of treatment; on the 3rd, 5th, 10th, 12th and 15th days of treatment, 500 mg of 5-fluorouracil combined with blood and incubated as described is administered. 14 days after the last injection of the mixture, the therapeutic effects are repeated in the same order, similar to the doses and treatment.

An example of a specific implementation of the method can serve as an extract from the medical history.

Patient M., born in 1956, medical history C-7025 / s, was admitted to the Department of Bone and Soft Tumor Tumors, RNIIII 05/05/2009 with a diagnosis of left breast cancer T2N1MO, st IIB, gr 2. Cytological analysis No. 12366 among leukocytes and lymphocytes detected atypical carcinoma cells. Cytological analysis No. 12502-503 infiltrating ductal s-h. Upon admission, the patient complained of a tumor in the left mammary gland, an increase in regional axillary lymph node, pain in the mammary gland, weakness, weight loss.

05/20/09 a complete blood count was performed:

date of Hb Er CPU Tp Le ESR PO Box s / i Ef Bf Mc Lf 05/20/09 124.0 4.1 0.9 58 ‰ 3.6 19 5 46 6 - 3 40 237.8

05/21/09. made a thermogram of the mammary glands (Figure 1). On the thermogram, the tumor occupies the entire volume of the left breast.

05/21/09. In the treatment room, a patient was sampled from a peripheral vein in two containers, 100 ml each. On both sides of the connecting tube of the dropper, inductors of the Gradient-3 apparatus were installed against each other, covering the connecting tube from daylight. Blood passing through the tube was simultaneously exposed to red light at a wavelength of 670 nm, a dose of 1-5 J / cm ² and a magnetic field of 5 mT induction, with a frequency of 0.3 Hz for 3 minutes. In the first container, 50 mg of doxorubicin was added, in the second 25 mg of methotrexate, 750 mg of 5-fluorouracil and 600 mg of cyclophosphamide. The contents of the containers were incubated for 40 minutes at a temperature of 37 ° C, after which the patient was introduced.

05/23/09. A second administration of chemotherapy drugs on autologous blood was carried out according to the method described above. 500 mg of 5-fluorouracil were introduced.

05/25/09. We carried out the third administration of a chemotherapy drug according to our method, 500 mg of 5-fluorouracil was introduced.

05/25/09. Repeated blood test:

date of Hb Er CPU Tr Le ESR PO Box s / i Ef Bf Mc Lf 05/25/09 126 4.3 0.88 63 ‰ 3.2 75 8 61 four - four 23 27.9

The patient's condition is satisfactory. No complaints. Skin and visible mucous membranes of normal color. In the lungs, vesicular breathing. Heart sounds are clear, rhythmic. A / D 120/80 mm Hg The abdomen is soft, painless on palpation. Physiological administration is normal. The patient does not show dyspeptic complaints of nausea, vomiting, diarrhea. The appetite is good. The toxic manifestations of chemotherapy are not noted.

05/28/09. The next administration of chemotherapy on autologous blood was carried out, exactly identical to the first administration. Dosage: 50 mg of doxorubicin, 25 mg of methotrexate, 750 mg of 5-fluorouracil and 600 mg of cyclophosphamide.

05/30/09. The fifth administration of the chemotherapy was carried out according to our method, 500 mg of 5-fluorouracil was introduced.

1.06.09. We carried out the sixth administration of a chemotherapy drug in our method, 500 mg of 5-fluorouracil was introduced.

06/04/09. The seventh administration of the chemotherapy was carried out according to our method, 500 mg of 5-fluorouracil was introduced.

The patient was discharged at the place of residence in satisfactory condition. Appearance after 2 weeks to resolve the issue of surgical removal of the tumor.

The proposed method was carried out the treatment of malignant breast tumors in 9 patients. In all cases, after the first chemotherapy course, the tumor was significantly reduced in size, which made possible its surgical removal.

The technical and economic effectiveness of the proposed "Method for the treatment of breast cancer" lies in the possibility of:

- reduce the toxic manifestations of antitumor chemotherapy drugs;

- reduce the size of the tumor formation;

- conduct surgical removal of the mammary gland.

Claims (1)

A method of treating breast cancer, including exposure to physical factors and the introduction of antitumor chemotherapy drugs, characterized in that the patient is taken from a peripheral vein in two blood vessels of 100 ml each, on each side of the connecting tube of the dropper, inductors of the physiotherapeutic apparatus are installed against each other and simultaneously exposed to red light with a wavelength of 670 nm, a dose of 1-5 J / cm ² and a magnetic field with an induction of 5 mT, a frequency of 0.3 Hz for 3 minutes; 50 mg of doxorubicin is added to the first container, 25 mg of methotrexate and 600 mg of cyclophosphamide and 750 mg of 5-fluorouracil are added to the second, the contents of the containers are incubated for 40 minutes at 37 ° C and the patient is introduced on the 1st and 8th days of treatment; on the 3rd, 5th, 10th, 12th and 15th days of treatment, 500 mg of 5-fluorouracil with autoblood and incubated as described is administered; 14 days after the last injection of a mixture of autologous blood with a chemotherapeutic drug, the therapeutic effects are repeated in the same order, similar to the doses and treatment.

Images